Recent Advances of Tumor Therapy Based on the CD47-SIRP? Axis

Cancer is still a major disease that is currently difficult for humans to overcome. When the expression of thecluster of differentiation 47 (CD47) is upregulated, tumor cellsinteract with the macrophage inhibitory receptor signal regulatoryprotein alpha(SIRP alpha) to transmit theDon't eat mesignal, therebyavoiding phagocytosis by the macrophages. Therefore, when theCD47-SIRP alpha axis is inhibited, the macrophages'phagocyticfunction can be restored and can also exert antitumor effects.This Review mainly introduces recent advances in tumor therapytargeted on the CD47-SIRP alpha axis, including the antibody andfusion protein, small molecule, gene therapy, cell therapy, and drug delivery system, to inhibit the function of CD47 expressed ontumor cells and promote tumor phagocytosis by macrophages. In addition, this Review also summarizes the current approaches toavoid anemia, a common side effect of CD47-SIRP alpha inhibitions, and provides ideas for clinical transformation

Automated summary

This Review introduces recent advances in tumor therapy targeted on the CD47-SIRP alpha axis, including various methods such as antibodies, fusion proteins, small molecules, gene therapy, cell therapy, and drug delivery systems. Inhibition of the CD47-SIRP alpha axis can restore the phagocytic function of macrophages and exert anti-tumor effects. Additionally, the Review summarizes approaches to avoid anemia, a common side effect of CD47-SIRP alpha inhibition, and provides ideas for clinical translation.